Plasma-derived liposomal factor VIII - Recoly

Drug Profile

Plasma-derived liposomal factor VIII - Recoly

Alternative Names: LongAte; LongEight; NecLip-pdFVIII; pdFVIII

Latest Information Update: 17 Mar 2015

Price : $50

At a glance

  • Originator Recoly
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 08 Jul 2012 Final efficacy data from a clinical trial in Haemophilia A published in the British Journal of Haematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top